Sanofi (SAN.PA) Stock Price
Sanofi Price
Over the last 19 years Sanofi grew revenue by 2.5% annually, reaching 46.72 B EUR. Earnings per share have grown at 4.2% per year over the last 19 years. For Sanofi, the net margin of 16.7% is broadly stable versus 15.9% a few years ago. At today's price the dividend yield works out to roughly 5.53%. The payout ratio is around 61% of earnings. The dividend has grown at 5.1% per year over the past 19 years. The consensus 12-month price target for Sanofi is 102.00 EUR, about 43.8% above where the stock trades today. Of 30 analysts, 19 rate the stock a buy — an overall Buy consensus.
Sanofi stock price
Sanofi business model & stock analysis
Frequently asked questions about Sanofi
The business model of Sanofi SA, a renowned pharmaceutical company, revolves around the research, development, manufacturing, and distribution of a wide range of healthcare products. Sanofi SA is committed to providing innovative solutions, convenient access to medication, and improving global health outcomes. Its diversified portfolio includes prescription drugs, vaccines, over-the-counter medicines, and health-related products across various therapeutic areas. The company consistently invests in cutting-edge research, collaborations, and mergers to advance healthcare advancements. Sanofi SA's focus on patient-centric initiatives, strategic partnerships, and global presence allows it to meet the evolving healthcare needs and make a positive impact on the lives of millions worldwide.
Sanofi SA is primarily active in the pharmaceutical and healthcare industries.
The main competitors of Sanofi SA in the market are Novartis AG, Pfizer Inc., and Merck & Co., Inc.
Sanofi SA, a leading pharmaceutical company, has a rich history and background. Established in 1973, Sanofi SA traces its origins to a merger between Sanofi and Synthélabo, two renowned French pharmaceutical companies. Over the years, Sanofi SA has expanded globally and is now headquartered in Paris, France. With a strong focus on research and development, Sanofi SA strives to deliver innovative medical solutions to improve the health and well-being of individuals worldwide. The company is involved in diverse therapeutic areas, including diabetes, vaccines, rare diseases, cardiovascular diseases, and more. Sanofi SA's commitment to excellence and patient care has solidified its position as a leading player in the pharmaceutical industry.
Sanofi SA, a leading pharmaceutical company, has achieved significant milestones throughout its history. Established in 1973, Sanofi SA has continuously strived for innovation and excellence in the healthcare industry. Some noteworthy achievements include the development of breakthrough medications, such as Plavix and Lantus, that have positively impacted global health. Sanofi SA has also made remarkable strides in areas such as diabetes management, oncology research, and vaccines. The company's commitment to research and development has led to numerous regulatory approvals and successful collaborations with other healthcare organizations. With its strong track record, Sanofi SA continues to revolutionize healthcare and improve patient outcomes globally.
Sanofi SA, a renowned pharmaceutical company, has a significant global presence. The company is primarily present in multiple countries and regions across the world. Some notable countries where Sanofi SA operates prominently include France, the United States, Germany, China, Japan, Brazil, and the United Kingdom. These regions offer Sanofi SA a vast market reach and strategic foothold, allowing the company to deliver its innovative healthcare solutions and medicines to numerous patients worldwide. With its widespread presence, Sanofi SA continues to make a positive impact on healthcare systems globally, addressing the needs of diverse populations and contributing to improved health outcomes.
Sanofi SA represents values of innovation, excellence, and integrity. As a global pharmaceutical company, Sanofi focuses on discovering, developing, and delivering healthcare solutions that enhance people's lives. The company's corporate philosophy centers around patient-centered approaches, scientific expertise, and ethical business practices. Sanofi is committed to addressing unmet medical needs, fostering a culture of diversity and inclusion, and ensuring sustainability in all aspects of its operations. With its dedication to improving global health, Sanofi SA strives to be a trusted partner and a leader in healthcare innovation.
Analysts currently set an average price target of 100.14 EUR for the Sanofi stock (median: 102.00 EUR), implying +41.2 % versus the latest price. The consensus is based on 30 analyst ratings.
30 analysts currently rate the Sanofi stock: 19 recommend buying, 10 holding and 1 selling. For 2026, analysts expect Sanofi to generate revenue of 48.89 B EUR and earnings per share of 8.59 EUR.
The Sanofi share (SAN.PA) is listed on 15 stock exchanges, including: NASDAQ (SNYNF), London (0O59.L), SIX (Zürich) (SNW.SW), XETRA (SNW.DE), Frankfurt (SNW.F), München (SNW.MU), Stuttgart (SNW.SG), Düsseldorf (SNW.DU).
Sanofi SA is a company headquartered in Paris that manufactures pharmaceutical products for a variety of diseases and medical areas. The company was formed in 2004 from the merger of Sanofi-Synthélabo and Aventis. Sanofi has various divisions, including Vaccines, Specialty Care, Consumer Healthcare, and Generics. The Vaccines division focuses on the development and production of vaccines for the prevention of infectious diseases such as influenza, polio, and meningitis. The Specialty Care division develops and distributes medications for rare diseases such as Fabry's disease, hemophilia, and multiple sclerosis. The Consumer Healthcare division produces over-the-counter drugs, vitamins, and supplements, while the Generics division manufactures generic drugs. Some of Sanofi's most well-known products include Lovenox, Plavix, Actonel, Allegra, and Nasacort. Lovenox is an anticoagulant used for the prevention and treatment of blood clots. Plavix is an antiplatelet medication used for cardiovascular conditions such as stroke and heart attack. Actonel is a bisphosphonate used for the treatment and prevention of osteoporosis. Allegra is an antihistamine used for allergies, while Nasacort is a nasal spray used for allergy treatment. Sanofi also focuses on the development of new medications and has an extensive pipeline of drug candidates in various stages of clinical development. Some of Sanofi's emerging products include Dupilumab for the treatment of atopic dermatitis and asthma, as well as Cablivi for the treatment of thrombotic thrombocytopenic purpura. Sanofi's business model is based on the manufacturing and marketing of pharmaceutical products and vaccines. The company invests significant resources in research and development of new drugs and has a strong presence in key markets worldwide. Sanofi offers a wide range of products in various therapeutic areas and provides a variety of medications for patients with different needs. The company also works closely with regulatory authorities to ensure that its products meet the highest quality standards and meet the needs of patients. Sanofi also has partnerships with other companies in the industry to accelerate the development of new products and prevent the spread of diseases. Overall, Sanofi's business model is focused on the development and marketing of innovative pharmaceutical products and vaccines to improve the well-being of patients worldwide. The company continues to invest in research and development and strives to meet the needs of patients in the fast-paced and constantly evolving world of the healthcare industry.
The expected revenue of Sanofi is 48.89 B EUR. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Sanofi is 10.41 B EUR. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Sanofi is currently 8.26. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Sanofi stock.
The price-to-sales ratio (P/S) of Sanofi is currently 1.76. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Sanofi stock.
The Eulerpool Quality Score for Sanofi is 5/10.
The ISIN of Sanofi is FR0000120578. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Sanofi is 920657. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Sanofi is SAN.PA. The ticker symbol is used to trade Sanofi shares on the stock exchange.
Sanofi stock
Sanofi Peer Group
Sanofi Ticker
Sanofi FIGI
All fundamentals and in-depth analysis of Sanofi
Our stock analysis for Sanofi stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Sanofi. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.